CSL Limited, the Australia-based parent company of CSL Behring, is buying Talecris Biotherapeutics Holdings Corp for $3.1 billion.

Talecris Biotherapeutics currently manufactures Koāte-DVI®, a plasma-derived factor VIII product for the treatment of bleeding episodes in patients with hemophilia A. The company also manufactures therapies for individuals with immune deficiency disorders and antithrombin III deficiency, a clotting disorder.

CSL Limited has over 9,000 employees in over 27 countries including major facilities in Australia, Germany, Switzerland and the U.S. CSL Behring, headquartered in King of Prussia, PA, specializes in plasma protein therapies.

Also in August, CSL Behring announced the availability of a new wireless patient data management tool called the HeliTraxSM System. Patients use the hand-held Helixate® FS device to transmit data to their hemophilia treatment center. According to CSL Behring, the new system is intended to improve “patient-physician communications” and treatment management.

Source: Reuters, August 13, 2008 and CSL Behring press release dated August 25, 2008